A Phase II Study of Reduced Therapy for Patients Newly Diagnosed with Average-Risk WNT-Driven Medulloblastoma

Print

Full Title

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients ACNS1422 (CIRB)

Purpose

Patients with average-risk medulloblastoma (a type of childhood brain tumor) are typically age 3 or older, have a tumor in the very back of the brain (an area called the posterior fossa), are able to have most or all of the tumor removed by surgery, and have not experienced cancer spread to other parts of the brain or spinal cord. Risk is the chance that the cancer will come back after treatment. Patients with a subtype of medulloblastoma called the WNT-subtype have been shown to have better survival than patients with other types of medulloblastoma.

Standard therapy for newly diagnosed average-risk WNT-subtype medulloblastoma includes surgery, radiation therapy, and chemotherapy. However, radiation therapy and chemotherapy can have long-term side effects. In this study, researchers want to see if a less intensive course of treatment using a lower radiation dose and less chemotherapy than usual can be given to children with newly diagnosed average-risk WNT-subtype medulloblastoma without increasing the chance that the tumor will come back.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • This study is for patients ages 3 to less than 22.
  • Patients must be newly diagnosed with average-risk WNT-subtype medulloblastoma.
  • Surgery for medulloblastoma is permitted, but patients may not have received prior radiation therapy or chemotherapy.

For more information about this study and to inquire about eligibility, please contact Dr. Stephen Gilheeney at 212-639-3973.

Protocol

19-040

Phase

II

Investigator

Co-Investigators